title: [Anti-inflammatory drugs and prostatic carcinoma: current state of evidence].
abstract: The epidemiological evidence for a protective effect of anti-inflammatory drugs against prostatic carcinoma is suggestive but not conclusive. Studies are limited by inadequate information on dose and duration of use and by methodological biases. Furthermore, potential benefits should be weighed against the known side effects of long-term use.
authors.affiliation: Klinik für Urologie, Kantonsspital, St. Gallen. hans-peter.schmid@kssg.ch
authors.forename: H-P
authors.initials: HP
authors.lastname: Schmid
authors.forename: D S
authors.initials: DS
authors.lastname: Engeler
authors.forename: R
authors.initials: R
authors.lastname: Theiler
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D015982:Bias; D014408:Biomarkers, Tumor / Q000097:blood; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D006801:Humans; D008134:Long-Term Care; D008297:Male; D015201:Meta-Analysis as Topic; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control*; D018570:Risk Assessment
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen